Lifitegrast: A novel inhibitor of integrin for dry eye disease
10.7501/j.issn.1674-6376.2017.06.030
- VernacularTitle:立他司特:黏附因子抑制剂类干眼症新药
- Author:
Fei ZHENG
;
Yanmei WANG
;
Qian ZHANG
;
Ying GONG
;
Yuanyuan GU
;
Guodong HUA
- Keywords:
lifitegrast;
ophthalmic solution;
integrin antagonist;
dry eye disease
- From:
Drug Evaluation Research
2017;40(6):880-884
- CountryChina
- Language:Chinese
-
Abstract:
Lifitegrast is a novel inhibitor of integrin,which can take effect by blocking the binding of intercellular adhesion molecule 1 and integrin lymphocyte function associated antigen 1.In July 2016,the U.S.Food and Drug Administration (FDA) officially approved the application of lifitegrast ophthalmic solution 5％ (commodity name XiidraTM).Clinical trials of the drug include a 12-week phase II clinical trial and three 12-week phase III clinical trials for dry eye disease patients.The results of clinical trials have demonstrated the efficacy and safety of the drug.Lifitegrast is the first FDA approved drug to improve and treat dry eye symptoms,and other similar drug is only cyclosporine.It is believed that in the near future clinical application of lifitegrast will be more extensive.
